MARATTO

article · Organic Letters

Discovery of <i>seco</i> -(9β-H)-Pimarane Diterpenoids from <i>Icacina oliviformis</i> with Synergistic Anti-Colorectal Cancer Activity

Abstract

Phytochemical investigation of the leaves of <i>Icacina oliviformis</i> led to the isolation of nine previously undescribed <i>seco</i>-(9β-H)-pimarane diterpenoids (<b>1</b>-<b>9</b>), along with two biosynthetic precursors (<b>10</b> and <b>11</b>). Their structures were elucidated using extensive NMR, HRESIMS, ECD (including Rh<sub>2</sub>(OCOCF<sub>3</sub>)<sub>4</sub>-induced ECD), and single-crystal X-ray diffraction analyses. Compound <b>1</b> represents the first natural 3,17-di-<i>nor</i>-pimarane, featuring a novel 2-oxaspiro[4.5]decan-3-one core fused to γ-butyrolactone and benzofuran units. Compounds <b>2</b>-<b>9</b> define a new structural subclass of naturally occurring 3,4-<i>seco</i>-17-<i>nor</i>-pimaranes. In the multicell line screening, compound <b>9</b> showed superior potency and selectivity against HT-29 (IC<sub>50</sub> = 5.32 μM) and SW620 (IC<sub>50</sub> = 9.92 μM) cells compared to 5-fluorouracil (5-FU). Moreover, it exhibited strong synergy with 5-FU in both HT-29 cells (CI = 0.0904) and CRC patient-derived organoids (CI = 0.2903), suggesting a significant dose-reduction potential for 5-FU. Mechanistic studies revealed that compound <b>9</b> induced apoptosis in HT-29 cells via ROS-driven selective activation of the ATF6-CHOP pathway.

Research topics

  • Sesquiterpenes and Asteraceae Studies
  • Natural product bioactivities and synthesis
  • Plant Toxicity and Pharmacological Properties

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1021/acs.orglett.6c00495

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.